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Background: Cancer is a serious health issue in China, but accurate national counts for cancer incidence are not
currently available. Knowledge of the cancer burden is necessary for national cancer control planning. In this study,
national death survey data and cancer registration data were used to calculate the cancer burden in China using a
Bayesian approach.
Methods: Cancer mortality and incidence rates for 2004–2005 were obtained from the National Cancer Registration
database. The third National Death Survey (NDS), 2004–2005 database provided nationally representative cancer
mortality rates. Bayesian modeling methods were used to estimate mortality to incidence (MI) ratios from the
registry data and national incidence from the NDS for specific cancer types by age, sex and urban or rural location.
Results: The total estimated incident cancer cases in 2005 were 2,956,300 (1,762,000 males, 1,194,300 females).
World age standardized incidence rates were 236.2 per 100,000 in males and 168.9 per 100,000 in females in urban
areas and 203.7 per 100,000 and 121.8 per 100,000 in rural areas.
Conclusions: MI ratios are useful for estimating national cancer incidence in the absence of representative
incidence or survival data. Bayesian methods provide a flexible framework for smoothing rates and representing
statistical uncertainty in the MI ratios. Expansion of China’s cancer registration network to be more representative of
the country would improve the accuracy of cancer burden estimates.
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Cancer is a leading cause of death in China [1]. Social
and economic changes and population aging contribute
to rapid increases in morbidity and mortality for most
cancers. Timely and accurate data on cancer are essen-
tial for effective cancer control. However; there are cur-
rently no national cancer incidence data and limited
cancer mortality data in China [2,3]. These deficiencies
limit the evidence available for national policy on cancer
control. An accurate estimate of the whole cancer bur-
den and major types of cancer in China would greatly
assist policy development.
The National Cancer Registration Network covered 43
regions from 20 provinces, with 5.53% of the national
population, in 2005 [4]. Although this network provides* Correspondence: chenwq@cicams.ac.cn
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reproduction in any medium, provided the orvery important data for China, there are shortcomings.
Most registries are located in the developed urban areas
of eastern China or are in known high-risk areas for can-
cers of the esophagus, stomach, liver and nasopharynx.
The unbalanced distribution means that the registries do
not paint a national representative picture of the cancer
burden. Moreover, a low rate of pathological diagnosis in
some registries and under-ascertainment limit the qual-
ity of the cancer registration data [5]. Thus the true bur-
den of cancer in China cannot be currently estimated
using cancer registration data alone.
For many developed countries, national estimates of
cancer incidence are calculated from national cancer regis-
tration, nationally representative sentinel cancer registries
or by constructing cancer incidence using national cancer
mortality and relative survival from sentinel cancer regis-
tries [6]. For most countries, however, cancer incidence
registries are not representative, nor are good survival data
available. Under such circumstances, cancer survival
would be indirectly represented using mortality to inci-
dence (MI) ratios from available cancer registries and ap-
plying them to nationally representative cancer mortalitytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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good estimate of (1-survival) for good quality data [7] and
the MI ratio has routinely been used to estimate incidence
in the absence of representative incidence and survival
data [8,9].
For incidence estimation, we adopted a Bayesian
approach to estimate the MI ratios. Our statistical
approach departed from that established by Jensen et al.
and used by the International Agency for Research on
Cancer (IARC) [8,9]. We modeled for the Poisson variabil-
ity in incidence and mortality rates, smoothed across age
using penalized splines, modeled for variation between
cancer registries using random effects and estimated the
statistical imprecision in the estimates of the national can-
cer incidence.
Our aims for this paper were to improve the methods
for indirect estimation of incidence and to apply those
methods to estimate cancer incidence in China using
updated national mortality data and regional cancer
registries data.
Methods
Mortality data
The Third National Death Survey (NDS) was carried out
in 2004 and 2005 to better understand mortality rates
and their trends in China. A total of 213 counties or
districts were selected as the survey points, including
160 national Death Surveillance Points, which collected
vital statistics for China, and 53 high-risk areas for cancer.
The Death Surveillance Points were selected to represent
the national population. They were based on counties and
stratified by geographic regions, with sampling further
stratified by urban or rural location and per capita gross
domestic product. The survey was specifically designed to
be nationally representative [10]. Our analysis included
158 Death Surveillance Points covering 142,660,482
person-years. Cancer site-specific mortality rates were cal-
culated by age, sex, and urban or rural location. Two death
surveillance points were excluded because of implausible
mortality rates.
Incidence data
The National Central Cancer Registry of China collected
cancer incidence data from population-based cancer
registries in China. We evaluated the quality of the cancer
registry data before our analysis (see Additional file 1:
Table S1). These quality control indicators for each regis-
try suggest that the data quality was relatively high with:
62.06% morphologically verified (ranging from 21.80 to
90.74%); 0.66 for the MI ratio (ranging from 0.53 to 0.87);
1.50% of death certificate only registration (ranging from
0.00% to 11.43%); and 2.59% of unspecified cancer sites
(ranging from 0.01% to 4.93%). Although there was variation
of the indicators between registries, overall quality wasacceptable. There were 32 cancer registries reporting can-
cer registration data for 2004 and 2005. The registries
identified new cancer cases from all hospitals, community
health centers, medical insurance and death registries (for
cases only identified by death certification). Registries
obtained information on cancer deaths from the death
surveillance system, which collected death information
from hospitals and the Civil Administration Bureau with
available cremation reports. Population information was
obtained from official registration records. For this study,
the data on cancer site (coded using ICD-10), sex and age
at diagnosis were retrieved from each cancer registry’s
database. Age was divided into 19 subgroups, including 0
and 1–4 years, five year age groups from 5–9 years to 80–
84 years, and 85 years or older. Cancer registry locations
were classified as urban (prefecture-level cities, provincial
capitals and municipalities directly under the Central
Government) or rural (counties and county-level cities).
Population data
Population data were obtained from the Statistics Bureau’s
population-based 1% sampling survey. The estimated na-
tional population was 1,307,560,000 in 2005. There were
282,071,816 males and 280,048,184 females in urban areas
and 378,907,152 males and 366,532,848 females in rural
areas. Regional population data in 2005 were extracted by
sex, age and urban or rural location.
Statistical analysis
The statistical method used is a generalization of that
used by Jensen et al. [8]. Whereas Jensen and colleagues
modeled mortality as a Poisson regression with the log
of incidence as an offset, we modeled both mortality and
incidence rates as Poisson regressions with shared pa-
rameters linking the two regression models. Moreover,
Jensen and colleagues fitted their models within a
frequentist generalized linear models framework, while
we fitted generalized linear mixed models within a
Bayesian Markov chain Monte Carlo framework. We
showed in Additional file 2 that the Poisson model used by
Jensen and colleagues does not incorporate the uncer-
tainty in incidence, and from a simulation sub-study, we
showed that their model leads to under-coverage, with
potential over-fitting during model selection. To briefly
outline our approach, we estimated the national cancer
incidence in 2005 by applying a set of age-, sex- and
site-specific MI ratios (by rural or urban location), pre-
dicted from the modeling of the region-specific registries
data, to the estimated 2005 national mortality data from
the 3rd NDS.
Regression models were developed separately for each
combination of sex and location (urban and rural). In
the following, age groups were indexed by i = 1,…,19 and
registries were indexed by j. We assumed that (a) registry
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(αi + uj) × (registry population), where αi represented
the log of the mean age-specific incidence rate and
uj represented random intercepts for the different
registries; (b) registry mortality had a Poisson distribution
with mean exp(αi + uj + βi + vj) × (registry population),
where βi represented the log of the mean age-specific MI
ratio and vj represented random intercepts for the differ-
ent registries and (c) NDS mortality had a Poisson distri-
bution with mean exp(γi) × (NDS population), where γi
represented the log of the age-specific mortality rate for
the NDS. We could then estimate the national incidence
using exp(γi-βi) × (national population).
The parameters αi, βi and γi were smoothed using
penalized splines. The means for αi were defined by
ϕ0 þ ϕ1 i−1019 þ
X6
k¼1Zikψk where: ∅0 and ∅1 were fixed
effects (unknown parameters with normal prior distribu-
tion with mean 0 and variance 104) for the constant and
linear term; Zik was from the design matrix for O’Sullivan
splines with knots indexed by k at ages 45, 55, 65 and
75 years, where the design matrix was calculated using R
code written by Wand and Ormerod, and Ψk were random
effects with normal prior distribution with mean 0 and
variance σα
2. We assumed that the precision σα
–2 had an
uninformative distribution. The parameters for βi and γi
were smoothed in a similar manner, with their own
precision terms. The random intercepts uj and vj were
assumed to have normal prior distribution with means
0 and variance σu
2 and σv
2, respectively. The inverse of
the variance terms, also called the precision terms, were
given Gamma (0.001,0.001) distribution. The models
used a 25 000 burn-in and then sampled every 25th iter-
ation for 25 000 iterations. The sampling properties
based on graphical plots indicated adequate mixing for
most parameters after a burn-in of approximately 5,000
and sampling for another 5,000. The choice of 25,000
for the burn-in and 25,000 for sampling was conserva-
tive to ensure good mixing for all of the sites. The 1000
samples were used to calculate 95% CIs for different
combinations of parameters, including the numbers of
incident cases, and age-specific and age-standardised
rates. The model was implemented using WinBUGS,
with model specification and data manipulation using R
and the R2WinBUGS and BRUGS packages. R and
WinBUGS code can be found in the Additional file 2.
SAS version 9.2 (SAS Institute, Cary, NC), R version
2.13.0 (www.r-project.org) and WinBUGS version 1.4.3
were used for the statistical analysis.Sensitivity analyses
Five sensitivity analyses were undertaken. Firstly, we
implemented the model using the SAS procedure PROC
MCMC, which implements a random walk Metropolisalgorithm rather than the Gibbs sampler popularized by
WinBUGS. The two models gave very similar age-specific
predictions (not shown in Results). The SAS procedure
required some effort to ensure good mixing of the param-
eters, including how to block the parameters for updating,
the choice of update distribution and the method for
constructing the initial covariance matrix. Secondly, we
assessed whether the use of MI ratios based only on can-
cer registry data gave different results to MI ratios based
on mortality data form NDS and incidence data from the
fewer cancer registries (26 in all) that covered NDS areas.
The ratio of NDS mortality to cancer incidence may be
more valid for the prediction equation since we used the
equation to predict national incidence from national mor-
tality, but we also expected the ratios to be less precise
since they were based on smaller populations. Third, we
examined the effect on the estimates of removing cancer
registries one at a time from the estimation of MI ratios.
Fourth, we compared the analysis results for MI ratios,
incidence rates and incident cases when MI ratios were
constrained to be 1 (using a logit transform) or less and
when they were unconstrained, using the WinBUGS pack-
age. When case fatality is high, mortality rates may be
greater than contemporary incidence rates if (i) inci-
dence is falling rapidly, (ii) incident cancer cases are
under-ascertained, (iii) mortality is over-ascertained, or
(iv) incident cancer cases are under-ascertained to a
greater degree than contemporary cancer deaths. Fifth,
we examined whether the estimates were sensitive to
the exclusion of ages less than 20 years. Re-fitting the
models with this restriction, we found that the estimated
number of cases did not vary significantly between models
that excluded ages less 20 years compared with estimates
from models that included all ages. For all sites, the rela-
tive differences were less than plus or minus 3%.
We also sought to validate the incidence estimates
internally by comparing registered incident cases, as
recorded by the Shanghai and Qidong registries for
2005, with estimated incident cases calculated by
multiplying real deaths data in the registry areas by the
estimated MI ratios. These two registries had 16.9%
and 0.9% of all incident cases in 2005 in the 32 regis-
tries. This approach follows the validation approach
used by Jensen and colleagues when they estimated
cancer incidence in the European Community from
available cancer incidence data, MI ratios and mortality
data [8].
We received an authorization to use the data for this
analysis from the National Central Cancer Registry. No
personal information (such as, name, ID number, home
address and personal contact details) were included
when the analysis data were extracted from the database.
Given the highly aggregated form of the data extraction,
an ethics approval was not required for this study.
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Mortality to incidence ratios for cancer in China
The MI ratio for all cancers was 0.74 in males and 0.61
in females (0.69 and 0.53 in urban areas and 0.79 and
0.71 in rural areas, respectively) (Table 1). Liver cancer
had the highest MI ratio in males (0.93) and females
(0.97). Breast cancer and cervical cancer had low MI ra-
tios (0.26 and 0.30 respectively). The cancer type specific
MI ratios in urban areas were lower than those in rural
areas, except for lung cancer in both sexes and liver can-
cer in women. Credible intervals about the MI ratios of
different cancers in either sex varied in width from less
than 1.0% to 46.6% of the point estimates. MI ratios
were most imprecise in rural areas.
Modeled age-specific MI ratios for individual major
cancer types were shown in Figure 1 for ages 15–19 years
and older; estimated ratios in younger age groups were
very imprecise because of small numbers. For all cancers
in both sexes, there was an initial short plateau in the
MI ratio followed by a rise to a peak in the oldest
people. The pattern of change in MI with age varied
among cancer types, but progressive increase with age
was a more-or-less constant feature.
Estimated cancer incidence rates in China
In urban areas, the estimated World age standardized
incidence rates for all cancers were 236.2 per 100,000
for males and 168.9 per 100,000 for females. In urban
areas, lung cancer had the highest incidence in males,
while breast cancer was the most common cancer in
females. In rural areas, the World age standardizedTable 1 Estimated MI ratios by site, location and sex, China 2
Site Overall
Male Female Male
MI (95% CI) MI (95% CI) MI (95%
Nasopharynx 0.64 (0.57,0.72) 0.64 (0.52,0.78) 0.56 (0.48
Esophagus 0.80 (0.76,0.84) 0.83 (0.78,0.90) 0.77 (0.71
Stomach 0.72 (0.69,0.75) 0.80 (0.77,0.84) 0.71 (0.68
Colorectal 0.47 (0.43,0.52) 0.47 (0.42,0.52) 0.42 (0.38
Liver 0.93 (0.87,0.98) 0.97 (0.91,1.02) 0.91 (0.84
Pancreas 0.91 (0.81,1.00) 0.92 (0.82,1.05) 0.91 (0.77
Lung 0.87 (0.83,0.92) 0.88 (0.82,0.96) 0.89 (0.81
Bone 0.85 (0.72,0.99) 0.87 (0.70,1.08) 0.68 (0.53
Breast 0.26 (0.23,0.29)
Cervix 0.30 (0.25,0.37)
Ovary 0.38 (0.32,0.45)
Prostate 0.43 (0.37,0.50) 0.34 (0.29
CNS 0.73 (0.66,0.83) 0.65 (0.53,0.79) 0.64 (0.54
Lymphoma 0.68 (0.53,0.86) 0.60 (0.47,0.77) 0.62 (0.43
All sites 0.74 (0.71,0.77) 0.61 (0.57,0.66) 0.69 (0.63incidence rates for all cancers were 203.7 per 100,000
for males and 121.8 per 100,000 for females. Stomach
cancer was the most common cancer for both men and
women in rural areas (Table 2). Credible intervals about
the age-adjusted incidence rates for different cancers in
either sex varied in width from 1.8% to 281.7% of the
point estimates. The estimates were more precise in
urban areas than in rural areas.
Estimated age-specific incidence rates for the major
cancer types were shown in Figure 2. In males, the rates
were very low in subjects aged less than 40 years. After
that age, they rose with increasing age in a typical
pattern to a maximum at 80–84 or 85+ years of age.
This pattern was similar in females except for breast and
cervical cancers. Estimated incidence of those cancers
began to rise at about 30–34 years of age, reaching a
peak in women aged 40s to early 50s and then fell pro-
gressively, with a small upturn in incidence of cervical
cancer in women in their 80s.
Estimated incident cases of cancer in China in 2005
We estimated that there were 2,956,300 new cases of
cancer diagnosed in China in 2005 (1,762,000 in males
and 1,194,300 in females). Lung cancer was the most
common cancer with an estimated 541,600 new cases in
2005 followed by stomach cancer (493,500), liver cancer
(411,300), esophageal cancer (276,600), colorectal cancer
(243,600) and female breast cancer (172,800) (Table 3).
The precision of these estimates varied by cancer type,
sex and location as expected due to the different size of
the subpopulations (see Additional file 3: Table S2).005
Urban Rural
Female Male Female
CI) MI (95% CI) MI (95% CI) MI (95% CI)
,0.68) 0.55 (0.39,0.80) 0.72 (0.62,0.82) 0.72 (0.59,0.88)
,0.83) 0.86 (0.76,1.03) 0.81 (0.77,0.87) 0.82 (0.76,0.89)
,0.74) 0.76 (0.70,0.84) 0.73 (0.69,0.77) 0.83 (0.78,0.87)
,0.46) 0.43 (0.38,0.49) 0.55 (0.45,0.65) 0.53 (0.43,0.63)
,1.00) 0.98 (0.90,1.09) 0.94 (0.87,1.00) 0.96 (0.89,1.03)
,1.06) 0.93 (0.78,1.11) 0.91 (0.80,1.03) 0.93 (0.80,1.04)
,0.97) 0.90 (0.78,1.05) 0.85 (0.81,0.90) 0.87 (0.82,0.92)
,0.89) 0.74 (0.52,1.08) 1.03 (0.86,1.23) 1.02 (0.80,1.28)
0.20 (0.17,0.23) 0.38 (0.34,0.43)
0.23 (0.19,0.31) 0.37 (0.27,0.51)
0.35 (0.28,0.43) 0.48 (0.37,0.59)
,0.41) 0.60 (0.46,0.77)
,0.77) 0.55 (0.40,0.77) 0.86 (0.75,0.97) 0.79 (0.68,0.92)
,0.95) 0.53 (0.38,0.78) 0.77 (0.62,0.90) 0.72 (0.57,0.88)
,0.74) 0.53 (0.45,0.59) 0.79 (0.76,0.82) 0.71 (0.66,0.76)
Males
Females
Figure 1 Modeled Age-specific MI Ratios for Major Cancers in 32 Cancer Registries in China 2005.
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The estimates of national incidence based on MI
ratios calculated from cancer registries in NDS areas
were similar to estimates based on MI ratios from all
cancer registries for all cancers and most cancer sites.
For cancers of the colon and rectum, nasopharynx,
lung and stomach, and for lymphoma, the differences
were less than 4.0% of the estimates of national inci-
dence and approximately equally distributed betweenestimates greater than and less than those based on
NDS areas. As expected, the intersection between the
cancer registries and the NDS gave considerably fewer
events, which led to imprecise estimates for several
cancer sites. Point estimates for the predictions for
some cancer sites varied appreciably under the sensi-
tivity analysis, where malignant tumors of brain had
14.5% few predicted cases and bone had 8.3% more
predicted cases.
Table 2 Estimated age-standardized cancer incidence rates per 100 000 by site, location and sex, China 2005a
Site Overall Urban Rural
Male Female Male Female Male Female
Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI)
Nasopharynx 2.9 (2.5,3.5) 1.1 (0.8,1.6) 3.4 (2.5,4.4) 1.2 (0.8,2.1) 2.6 (2.1,3.3) 1.0 (0.7,1.5)
Esophagus 23.9 (22.1,25.8) 9.6 (8.6,10.6) 17.5 (15.4,19.9) 5.7 (4.6,7.0) 28.5 (25.9,31.5) 12.5 (11.1,14.0)
Stomach 42.1 (39.6,44.9) 17.4 (16.0,19.0) 37.1 (34.2,40.3) 15.3 (13.3,17.8) 45.6 (41.9,49.9) 18.9 (17.0,21.0)
Colorectal 16.6 (14.5,19.2) 11.8 (10.2,14.0) 22.4 (19.3,26.3) 15.6 (13.1,18.8) 12.3 (9.7,16.0) 8.9 (6.9,11.9)
Liver 36.8 (34.3,39.6) 12.7 (11.6,13.9) 33.2 (29.4,37.2) 10.7 (9.4,12.3) 39.5 (36.2,43.2) 14.2 (12.7,15.9)
Pancreas 3.2 (2.7,3.8) 2.2 (1.9,2.6) 4.6 (3.7,5.7) 3.4 (2.7,4.3) 2.1 (1.7,2.7) 1.4 (1.1,1.8)
Lung 45.6 (42.8,48.8) 19.7 (17.8,21.6) 53.0 (47.7,59.5) 23.1 (19.5,27.1) 40.2 (37.1,43.6) 17.0 (15.3,18.9)
Bone 2.3 (1.8,3.0) 1.5 (1.1,2.1) 2.9 (1.9,4.4) 1.8 (1.1,3.0) 1.8 (1.4,2.5) 1.2 (0.8,1.8)
Breast 20.4 (17.5,23.8) 31.2 (25.6,38.4) 11.5 (9.4,13.9)
Cervix 8.1 (6.3,10.5) 9.0 (6.4,12.6) 7.3 (5.0,10.5)
Ovary 3.6 (2.8,4.7) 6.0 (4.5,8.3) 1.6 (1.1,2.3)
Prostate 4.2 (3.4,5.5) 6.6 (5.0,8.7) 2.5 (1.7,3.9)
CNS 4.7 (3.9,5.7) 3.9 (3.1,5.1) 6.1 (4.5,8.1) 5.1 (3.4,7.5) 3.6 (2.9,4.7) 2.9 (2.3,3.9)
Lymphoma 2.5 (1.9,3.4) 1.7 (1.2,2.4) 3.3 (2.1,5.2) 2.3 (1.5,3.7) 1.8 (1.3,2.5) 1.1 (0.8,1.8)
All sites 217.7 (206.7,228.9) 143.0 (132.1,156.8) 236.2 (216.2,258.3) 168.9 (148.8,198.0) 203.7 (192.4,215.1) 121.8 (111.7,133.4)
aRates were directly age-standardized to the World population.
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ratio, made only small changes to burden estimates.
The effect on all cancers ranged from 0.01% to 1.22% of
the total incidence estimates. Registries with very large
populations did not strongly influence the estimates, for
example, 0.41% from removal of Beijing registry and
0.59% Shanghai registry. Shenyang registry had the lar-
gest effect (1.22%), possibly because of its quite large
population (more than 3 million) and comparatively
high incidence rates of cancers with high MI ratios,
such as lung cancer and liver cancer.
When we compared cancer burden calculated with MI
ratio estimates constrained to 1 or less with that calcu-
lated with no constraint on the MI ratio, our primary
analysis, the different for all cancers was 6% (95% CI: 6%
to 14%) in males and 0% (95% CI: -9% to 7%) for females.
For individual cancers, the two were different by not more
than 8% in males and in females.
Internal validation
When estimated national MI ratios were applied to
Shanghai cancer mortality data the overall cancer incidence
in Shanghai was estimated at 5.4% in males and 9.5% in
females higher than its observed incidence. Similarly for
Qidong, the estimated incidence was 2.3% less in males and
4.7% higher in females than the observed incidence.
Discussion
We estimated a total of 2.96 million incident cases of
cancer in 2005 in China by using data from 32 cancerregistries and the third National Death Survey, and a
Bayesian model. Among all cancers, lung, stomach, liver,
esophageal, colorectal and female breast cancer were the
most common cancers. The incidence of those cancers
was higher in males than in females (except for breast
cancer). For cancers of the esophagus, stomach and liver
the incidence was higher in rural locations than in urban
locations and for cancers of the lung, female breast and
colorectum, the reverse patterns was observed. MI ratios
were not consistently different between the sexes but,
with few exceptions, were generally higher in rural than
urban locations.
There have been two recent efforts to estimate can-
cer burden in China. First, the IARC estimated that
there were 2.82 million new cancer cases and 1.96 mil-
lion cancer deaths in China in 2008 in its GLOBOCAN
project [9]. It estimated age, sex and site-specific MI
ratios using 2003–2005 data from 36 Chinese cancer
registries. The authors followed the model from Jensen
et al. [8]. Younger age groups were combined and age
was smoothed using polynomials up to order 5, requir-
ing a model selection step using likelihood ratios
[8,9,11]. National incidence rates for the rural and
urban populations of three regions (East, Middle and
West) were calculated from the products of the MI ra-
tios and mortality rates from the NDS (2004–2005)
and incident numbers were estimated by multiplying
by the regional populations for 2008. These numbers
were probably under-estimated for 2008 because of the
use of mortality data for 2004–2005 and generally
Males
Females
Figure 2 Estimated Age-specific Incidence Rates for Major Cancers in China, 2005.
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authors chose to stratify by both region and urban/
rural location, which would result in only a few registries
contributing to some strata. If the registries contribut-
ing to a stratum were not representative, then their MI
ratios would poorly predict incidence in that stratum.
Moreover, the predictions at younger and older ages were
likely to be unstable or inaccurate, as polynomials are
imprecise at data boundaries. No measures of uncer-
tainty were presented.Second, Ren and colleagues compared two methods to
estimate cancer incidence in China using data and
methods similar to those used in GLOBOCAN [12].
Their preferred method gave estimates of 2.58 million
incident cancer cases and 1.79 million cancer deaths in
2005. For calculating the MI ratios under this method,
smaller cancer registries were given more weight by div-
iding the numbers of incidence and mortality cases by
the square root of the registry population. They did not
quantify uncertainty; nor could they validly estimate
Table 3 Estimated numbers of incident cancer cases in 1000 s by site, and sex, China 2005
Site Overall Urban Rural
Male Female Male Female Male Female
Cases (95% CI) Cases (95% CI) Cases (95% CI) Cases (95% CI) Cases (95% CI) Cases (95% CI)
Nasopharynx 24.1 (21.6,27.3) 9.6 (7.7,12.0) 12.2 (9.8,14.6) 4.7 (3.1,6.7) 12.0 (10.3,14.1) 4.8 (3.9,6.0)
Esophagus 194.8 (185.4,204.9) 81.8 (75.4,87.5) 59.7 (55.3,64.8) 21.0 (17.6,24.3) 135.0 (126.8,143.8) 60.6 (55.7,65.6)
Stomach 343.9 (329.9,358.5) 149.6 (142.3,157.4) 128.8 (123.0,135.1) 56.9 (51.7,62.3) 214.9 (202.7,229.6) 92.7 (87.6,98.5)
Colorectal 134.9 (122.9,149.0) 99.7 (89.9,111.5) 77.3 (70.2,85.6) 57.1 (50.2,64.8) 57.4 (47.5,69.9) 42.4 (35.4,52.3)
Liver 303.3 (286.2,321.8) 108.0 (101.9,114.7) 117.9 (107.3,128.6) 39.7 (35.9,43.7) 185.4 (172.5,198.0) 68.4 (63.1,73.9)
Pancreas 26.1 (23.5,29.3) 19.2 (16.8,21.8) 15.9 (13.5,18.9) 12.4 (10.2,14.8) 10.2 (8.8,11.6) 6.7 (5.8,7.9)
Lung 373.0 (354.5,394.8) 168.6 (155.3,181.8) 183.1 (166.9,202.7) 85.4 (73.4,98.1) 190.1 (178.9,201.5) 83.0 (78.0,88.7)
Bone 17.7 (15.0,21.0) 11.7 (9.3,14.6) 9.4 (7.1,12.2) 6.3 (4.3,8.8) 8.3 (6.8,9.9) 5.4 (4.2,6.9)
Breast 172.8 (154.3,194.9) 119.2 (102.8,140.5) 53.5 (47.2,59.7)
Cervix 68.5 (56.1,84.0) 35.6 (27.0,45.5) 33.0 (24.5,44.9)
Ovary 29.9 (25.0,36.2) 22.5 (17.9,28.6) 7.3 (5.8,9.5)
Prostate 34.8 (29.6,40.4) 22.8 (18.7,27.4) 11.8 (9.1,15.7)
CNS 35.6 (31.3,40.2) 30.5 (25.0,37.2) 19.8 (15.9,23.5) 17.6 (12.6,23.9) 15.8 (13.9,18.2) 12.8 (10.8,15.0)
Lymphoma 19.8 (15.5,25.3) 13.5 (10.4,17.4) 11.5 (7.5,16.6) 8.4 (5.7,12.1) 8.3 (6.9,10.2) 5.1 (4.0,6.5)
All sites 1762.0 (1686.9,1836.6) 1194.3 (1115.1,1295.7) 811.1 (751.4,878.5) 619.3 (551.2,716.6) 950.2 (907.8,987.1) 575.0 (534.8,619.3)
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count divided by the square root of population does not
have a Poisson distribution. Our estimate of 2.96 million
was about 15% higher than that obtained by Ren el al using
more conventional methods. One possible explanation
for the difference in estimates is that we used a formal
statistical model for the variation between cancer re-
gistries using random effects, while Ren and colleagues
used arbitrary weights for each cancer registry.
Modeling within a Bayesian MCMC framework allowed
for the ready calculation of credible intervals (CIs) for MI
ratios, age-standardized rates and numbers of incident
cancers. We were able to use an appropriate statistical
model for the incidence and mortality rates, to flexibly
smooth across age groups using random effects, and to
estimate reliable age-specific estimates. Moreover, to take
better account of variation between the cancer registries,
we included registry-level random effects for cancer inci-
dence and for MI ratios. Care may be required in the in-
terpretation of the CIs, as the registry-level random effects
may under-estimate the uncertainty associated with gener-
alizing the MI ratios from the cancer registries to the
national population. One strength of our approach is that
we could provide a reasonable lower bound on the level of
uncertainty for these estimates. The uncertainty was larger
for rural areas, where less of the population was repre-
sented and cancer registrations tend to be less reliable. Un-
certainty was also greater for younger and older age groups,
where smaller numbers of cancers lead to wider CIs.
Some indication of the uncertainty due to imperfect
measurement systems was given by the results of oursensitivity analysis on the source of the mortality data.
Generally, use of NDS mortality instead of mortality
recorded by cancer registries to estimate MI ratios pro-
duced incidence estimates that were within 4% of those
obtained using only the registry data, which suggests good
agreement between the two approaches in the recording
of cancer mortality. There was, however, much greater
variance than this for some cancers, which may reflect sys-
tematic error in one or other cancer mortality data collec-
tion. For the sensitivity analysis were the MI ratios were
estimated from the overlap between cancer registries and
the NDS, the national burden of bone cancer was 8%
higher, which may, perhaps, reflect a greater tendency for
the NDS to records deaths from secondary cancer in bone
as death from primary cancer, while the national burden
for brain cancer was 14.5% lower, which may indicate a
tendency for the stigma attached to brain cancer to lead to
under-recoding of deaths from it in the NDS. It is also im-
portant to note that the 32 cancer registries on which our
reported national cancer incidence was based covered a lit-
tle less than 5% of China’s population, and most were lo-
cated in the east of China, which was more developed
economically than the west of the country. Thus use of lim-
ited cancer registry data to estimate national burden will al-
most inevitably lead to some bias in the estimate. MI ratios
by cancer registry are available in Additional file 4: Table
S3. As more registries become available, it will be useful to
investigate whether there is variation of burden in China
across an east–west axis and across a north–south axis.
On a technical note, we assumed that the counts for
incidence and mortality are statistically independent,
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as we expect that deaths today will be a result of inci-
dent cancers over the preceding years. However, formal
statistical modeling for this autoregressive relationship,
such as by use of MIAMOD, would require a good
characterization of survival, which is not currently avail-
able in China [6,13].
Although the sensitivity analyses suggest that our
results are not unduly sensitive to a number of meth-
odological issues, we have no way of fully validating
the burden estimates. Jensen et al. sought to validate
their use of MI ratios to estimate burden, later taken
up by IARC, by applying the modeled MI ratios for the
European Community to mortality data from Scotland
and Denmark and comparing predicted with observed
cancer incidence for these two regions [8]. Data from
Scotland and Denmark were included in the MI calcu-
lations, which would tend to reduce the difference be-
tween observed and predicted incidence. We applied a
similar approach using two registries, Shangahi and
Qidong. The percentage variation of estimated from
observed incidence rates in these registries – 2.3% to
9.5% depending on sex and registry – was similar to
that in the European registries – 1.9% to 7.9%. Had the
registries been a representative sample from a larger
whole, we could have used cross-validation; however,
the registries were not representative and we used all
available. Following a reviewer’s suggestion, future
work could use simulation to compare several methods
for burden calculation. This would allow the simula-
tion of cancer incidence and mortality under different
missingness mechanisms, or for bias in the selection of
cancer registries, and then assess the degree of bias
from the different methods relative to the hypothesized
“truth”.
There are several other models available to model inci-
dence and mortality. We recently developed a generalized
linear model where mortality has a binomial distribution
conditional on the sum of mortality and incidence [14]
(see Additional file 2). It would be useful to adapt this
model using a smooth function on the logit scale, with the
odds ratio providing an estimate of the MI ratio. In related
work, Clèries et al. predicted incidence based on a model
for the difference between incidence and mortality rates
[15]. Their model can be interpreted as modeling survival
by the predicted difference divided by the incidence
rate. However, survival does not in general appear to
be inversely proportional to the incidence rate, so the
age-specific intercept would need to adjust for changes
in incidence.
While the main aim of this analysis was to produce a
probably more accurate estimate of overall cancer burden
in China and the burden of major types of cancer, the MI
ratios may also be of interest. The observation that the MIratios were generally higher in rural than in urban areas
suggests there is an important difference in resources
for cancer control between these areas in China (see
Additional file 4: Table S3). They might also indicate a
greater level of under-ascertainment of incident cancers
(or over-ascertainment of deaths) by rural than urban
registries, particularly given the greater prevalence of
MI ratios of 1 in rural areas (which means that the
recorded number of deaths was equal to or greater than
the number of registered cases).
Although these national estimates are only synthetic
substitutes for the true cancer incidence in China and
there are uncertainties about these estimates, they provide
important information for cancer control in China. Based
on our estimates, there were more than a half million
(541,600) new diagnoses of lung cancer in China in 2005.
The number of lung cancer diagnoses has been predicted
to increase in the future due to the aging population, high
smoking rates and rising tobacco consumption, especially
in younger generation, in China <http://global.tobaccofreekids.
org/files/pdfs/reports_articles/2007%20China%20MOH%
20Tobacco%20Control%20Report.pdf>. It is well established
that tobacco smoking causes lung cancer and many other
cancers (including stomach, esophagus and liver cancer).
Thus, tobacco control is of particular importance in China
and should be considered a high priority in national can-
cer control plan. Evidence in tobacco control from other
countries indicated that healthcare professionals have a
critical role to play in setting an example for the general
public; for example, a high quit rate among doctors in the
United Kingdom had a major impact in reducing lung
cancer rate. In the shorter term, their advice encouraging
smoking cessation has been shown to be effective in per-
suading older adults to quit leading to a significant reduc-
tion in lung cancer rates. In the longer term, discouraging
younger people from initiating smoking is particularly
important in China because the smoking rate is rising in
the younger generations. Other strategies, including the
introduction of anti-smoking legislation and increasing
cigarette taxes, have been shown to be effective in tobacco
control. Some progress has been made in this regard in
China, but we still have a long way from being a smoke-
free society.
Prevention is generally preferable to cure especially for
cancers with very high fatality, such as cancers of the lung,
stomach, esophagus and liver. But it may take another
decade to see the benefits of cancer control policies such
as tobacco control in China. Therefore, it is equally im-
portant to ensure that current and future cancer patients
will have adequate access to effective treatment including
palliative care. We found a total of 2.96 million new can-
cers were diagnosed in 2005 in China; it is a huge chal-
lenge for the Chinese health system to provide adequate
health care for this group of patients. To provide health-
Chen et al. BMC Cancer 2013, 13:458 Page 10 of 10
http://www.biomedcentral.com/1471-2407/13/458care to all these cancer patients, we need an adequate
supply of health professionals including skilled cancer
surgeons, medical oncologists and cancer nurses, and
good access to radiation therapy and cytotoxic drugs and
supportive care. We believe that priority in treatment
should be given to improving the efficiency of existing
treatment in a cost-effective way, especially to those living
in rural areas and those who cannot afford expensive
cancer treatment. All these should be important element
of cancer control plan in China.
Early detection of cancer is another important element
of cancer control plan which is extremely important in
China, as many cancer patients are diagnosed at an
advanced stage. Rising awareness of the general public
and education of primary and secondary care providers
about the early signs of cancer may be the most import-
ant and cost-effective way to detect cancer at the earliest
time.
Conclusions
The limited population coverage and unrepresentative
distribution of the cancer registries in China will continue
to create uncertainty about estimates of the national
cancer burden. The uncertainty would limit the use of
these national estimates in developing effective cancer
control policy in China. Therefore, there is a pressing
need to establish a system for more complete and more
representative national cancer registration to support
effective cancer control. It may take more than a decade
to establish such a national cancer registration system.
In the absence of such complete and representative data,
creative, informed use of limited regional population-
based cancer registries data, with appropriate statistical
methods, can be a valuable tool for development of cancer
control policy in China.
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